5-amino-1mq vs nad+ Peptide Dosing Guide: Oral Protocol, Reconstitution & Safety (2026) For laboratory research use only. 5-amino-1mq peptide: complete guide to

The Guidelines are not intended as a substitute for the advice or professional judgment of a health care professional, nor are they intended to be the only approach to the management of clinical problem

Regulatory watch Last reviewed Jul 1, 2026 Next review Jul 29, 2026 Evidence snapshot AOD-9604 was developed by Metabolic Pharmaceuticals (Australia) as a modified C-terminal fragment (residues 177-191) of human growth hormone, designed to retain lipolytic activity without growth-promoting effects

All medical content on this blog is created using reputable, evidence-based sources and is regularly reviewed for accuracy and relevance

78 H 123 N 23 O 23 S 2 AOD-9604 Mechanism of Action Models the C-terminal lipolytic domain of human growth hormone (residues 176191) with an added N-terminal tyrosine

Direct appetite suppression is a GLP-1 mechanism, not a growth hormone mechanism